[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Costa et al., 2021 - Google Patents

Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults

Costa et al., 2021

View HTML
Document ID
12760550678469766602
Author
Costa R
Bueno F
Albert E
Torres I
Carbonell-Sahuquillo S
Barrés-Fernández A
Sánchez D
Padrón C
Colomina J
Carreño M
Bretón-Martínez J
Martínez-Costa C
Navarro D
Publication year
Publication venue
Clinical Microbiology and Infection

External Links

Snippet

Objectives Studies comparing severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) RNA load in the upper respiratory tract (URT) between children and adults—who either presented with coronavirus disease 2019 (COVID-19) or were asymptomatic—have yielded …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses

Similar Documents

Publication Publication Date Title
Costa et al. Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults
Osterman et al. Impaired detection of omicron by SARS-CoV-2 rapid antigen tests
Osman et al. Re-positive coronavirus disease 2019 PCR test: could it be a reinfection?
Scohy et al. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis
Mitchell et al. Evaluation of the COViD19 iD NOW EUA assay
Böger et al. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19
Li et al. Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2
Imai et al. Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19
Landaas et al. Diagnostic performance of a SARS-CoV-2 rapid antigen test in a large, Norwegian cohort
Ayers et al. Acute flaccid myelitis in the United States: 2015–2017
Lephart et al. Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type
Merckx et al. Transmission of SARS-CoV-2 by children
Perez-Garcia et al. Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study
Granados et al. Comparison of asymptomatic and symptomatic rhinovirus infections in university students: incidence, species diversity, and viral load
Bossuyt Testing COVID-19 tests faces methodological challenges
Pas et al. First international external quality assessment of molecular diagnostics for Mers-CoV
Mat Jusoh et al. Performance evaluation of commercial dengue diagnostic tests for early detection of dengue in clinical samples
Holborow et al. The clinical sensitivity of a single SARS-CoV-2 upper respiratory tract RT-PCR test for diagnosing COVID-19 using convalescent antibody as a comparator
Ong et al. Comparison of the GeneFinderTM COVID-19 Plus RealAmp Kit on the sample-to-result Platform ELITe InGenius to the national reference method: An added value of N gene target detection?
Júnior et al. Prevalence of COVID-19 in children, adolescents and adults in remote education situations in the city of Fortaleza, Brazil
Nijhuis et al. Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department
Jiang et al. Establishment of a quantitative RT-PCR detection of SARS-CoV-2 virus
Krenn et al. Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to detect Omicron-BA. 4 and-BA. 5
Nuchnoi et al. Applicability of a colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for SARS-CoV-2 detection in high exposure risk setting
Makhmalbaf et al. Detection of SARS-CoV-2 genome in stool and plasma samples of laboratory confirmed Iranian COVID-19 patients